[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer39s-disease-ad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer39s-disease-ad":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,73,99,128,164,195,216,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100586961","development-of-measures-to-screen-for-financial-hardship-in-alzheimers-disease-and-dementia-100586961",false,"NCT06922188","Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia","AD\u002FADRD","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* One of the following:\n\n  * Clinical diagnosis of Alzheimer's disease or related dementia\n  * Being a caregiver to individuals with clinical diagnosis of Alzheimer's disease or related dementia\n* Able to read and speak English or Spanish\n* Able to provide informed consent\n* Residing in the United States\n\nExclusion Criteria:\n\n• Cognitive impairment precluding informed consent",true,"ALL","18 Years",{"count":20,"type":21},2460,"ESTIMATED","OBSERVATIONAL","Alzheimer's Disease and related dementias (AD\u002FADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD\u002FADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work productivity and income for their caregivers that can last for decades after disease onset, and difficulty deciding between nursing home care or home-based care while negotiating insurance coverage. People from historically marginalized groups can experience a double disparity with fewer financial resources to manage AD\u002FADRD and a greater risk of AD\u002FADRD. Screening for financial hardship in AD\u002FADRD is key for addressing the needs of patients and caregivers but critical barriers include a lack of suitable screening measures. Current measures are very general and meant for people without chronic medical conditions or are specific to other diseases. To fill this gap, this study will create a suite of measures that can screen for financial hardship in people with AD\u002FADRD and their families and caregivers. The measures will include a set to assess caregiver burden; a set to assess patient hardship as reported by the caregiver for patients who cannot report for themselves; and a set of patient-reported measures for patients that are able to report for themselves. To create these financial hardship screening measures, the project will conduct the following aims. Aim 1- Develop financial hardship screening measures for Alzheimer's Disease and related dementias: Using interviews with both caregivers and people with AD\u002FADRD, key indicators of financial hardship that are unique to AD\u002FADRD and the point in the lifespan in which it occurs will be identified. The ways that social and caregiver network size affect financial hardship will also be explored. Using the interviews and previous measures, preliminary measures will be created and will be reviewed by experts and a patient and caregiver advisory board. Aim 2- Create item response theory-based screening measures for financial hardship measures in Alzheimer's Disease and related dementias: Large samples of people with AD\u002FADRD (n=1000) and caregivers (n=1000) will be surveyed and item response theory will be used to evaluate and revise the measures and create scoring algorithms. A sample of additional caregivers matched to primary caregivers (n=400) will also be recruited to evaluate interrater reliability of the measures. Aim 3- Evaluate the financial hardship measures across patient and caregiver populations: Using the sample from Aim 2 and item response theory, we will evaluate the financial hardship screening measures across the following groups to ensure they are unbiased and reflect true differences: race\u002Fethnicity; patient comorbidities; stage of AD\u002FADRD; caregiver relationship; social network size; number of caregivers; financial support provided; and caregiver's own health status (disability, comorbidities). The resulting measures will improve identification of financial hardship in AD\u002FADRD.",[25,26,27],"Financial Hardship","Alzheimer's Disease (AD)","Alzheimer's Disease and Related Dementia (ADRD)",[29,30,31,32,33],"Social Determinants of Health","Financial Toxicity","Financial Burden","Dementia","Alzheimers Disease","RECRUITING","2026-08-17",{"date":37,"type":38},"2026-08-19","ACTUAL",{"date":40,"type":38},"2025-03-31",{"date":42,"type":21},"2029-12-18",{"name":44,"class":45},"Fred Hutchinson Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100651777","phase-3-a-clinical-study-evaluating-the-diagnostic-performance-and-safety-of-pet-for-the-deposition-of-a-plaques-in-the-brain-of-participants-with-normal-cognitive-function-mci-and-ad-using-18ffluorbetazine-injection-100651777","NCT07764679","A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection","A Multicenter Phase III Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection","Inclusion Criteria:\n\n1 1. Men or women aged ≥ 40 years (including the threshold age). 2. Men or women with fertility must use effective contraceptive measures during the study period. Effective contraceptive measures include sterilization, intrauterine hormone devices, condoms, birth control pills, abstinence, or vasectomy.\n\n3\\. Meet the diagnostic criteria for normal cognitive function, Mild Cognitive Impairment (MCI), or Alzheimer's disease (AD).\n\n4\\. Participants voluntarily join the study, can cooperate with the experimental observations, and sign a written informed consent form. For participants with AD dementia, the informed consent form must be signed together with their legal guardian. If the participant is unable to sign the informed consent form due to limited cognitive ability or other reasons, the participant's signature space may be left blank, with the reason documented. The guardian should sign in the designated space for explanation.\n\nExclusion Criteria:\n\n1. Known allergy to \\[18F\\]Fluorbetazine injection or its excipients.\n2. Presence of previously implanted metal devices that are incompatible with MRI examinations, including pacemakers, defibrillators, insulin pumps, cochlear implants, intraocular metal implants, nerve stimulators, or CNS aneurysm clips; or suffering from claustrophobia or intolerance to imaging procedures for other reasons.\n3. Cognitive impairment caused by reasons other than Alzheimer's disease (AD).\n4. Cranial MRI scan shows one or more of the following results:\n\n   * More than 2 infarctions with a diameter greater than 2 cm in any part of the brain;\n   * Infarctions of any diameter in key areas such as the thalamus, hippocampus, entorhinal cortex, hippocampal gyrus, gyrus, cortex, or other subcortical gray matter nuclei;\n   * Fazekas Scale grading of white matter lesions \\> 2;\n   * Presence of brain tumors, intracranial infections, or cerebral hemorrhage, and deemed unsuitable for participation in this study by the researchers.\n5. Current clinically significant psychiatric illnesses, such as severe depression or schizophrenia, based on medical history, and the researchers have assessed that the imaging process cannot be completed. Researchers should carefully consider whether participants with dementia and behavioral disorders who may require psychiatric medication can complete the imaging process.\n6. Received radiopharmaceutical imaging or treatment within at least 5 half-lives prior to screening.\n7. Suffering from other serious and\u002For poorly controlled and\u002For unstable diseases, and deemed unsuitable for participation in this study by the researcher.\n8. Positive test results for human immunodeficiency virus (HIV) antibodies or Treponema pallidum antibodies.\n9. History of alcohol or drug abuse.\n10. Pregnant or lactating women with positive pregnancy test results during the screening period (including premenopausal women who have not undergone surgical sterilization and women within one year after menopause).\n11. Participated in any clinical trials within 4 weeks prior to enrollment and used investigational drugs; or those who plan to participate in any clinical trials during the study period.\n12. Other situations deemed unsuitable for participating in this clinical trial by the researchers.\n\nParticipants with Normal Cognitive Function\n\n1\\. Any evidence suggesting the possibility of AD from previous MRI, CT, or other biomarker studies.\n\nMCI and AD Dementia Participants\n\n1. Received anti-Aβ targeted therapy drugs, such as lecanemab monoclonal antibody, or treated or prophylactic anti-Aβ vaccines.\n2. Suffering from neurodegenerative diseases other than AD, including but not limited to Parkinson's disease, Pick's disease, frontotemporal degeneration (FTLD), Huntington's disease, Down syndrome, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, or progressive supranuclear palsy (PSP).\n3. Previously or currently diagnosed with dementia other than AD, including but not limited to Parkinson's disease dementia, Lewy body dementia, frontotemporal dementia, vascular dementia, mixed dementia, etc.","40 Years",{"count":56,"type":21},400,"INTERVENTIONAL",[59],"PHASE3","A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using \\[18F\\]Fluorbetazine injection.",[62,26],"Mild Cognitive Impairment (MCI)","2026-08-13",{"date":65,"type":38},"2026-08-14",{"date":67,"type":38},"2025-06-20",{"date":69,"type":21},"2028-12-31",{"name":71,"class":72},"HTA Co., Ltd.","INDUSTRY",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100648491","phase-3-an-evaluation-of-treatments-for-sustained-clinical-response-18-months-in-symptomatic-alzheimers-disease-100648491","NCT07724132","An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease","Alzheimer's Disease- Systematic Multi-Arm Adaptive Randomised Trial","AD-SMART","Inclusion Criteria\n\n* Patient meets all inclusion criteria:\n\n  1\\. Adults aged ≥55 years on the day of screening, no upper age limit 2. Either:\n  1. Confirmed clinical diagnosis of Alzheimer's Disease (AD)\n  2. Confirmed clinical diagnosis of Mixed Dementia consisting of Alzheimer's Disease and Vascular Dementia 3. Mini Mental State Examination score of ≥17 4. Confirmatory blood biomarker testing (pTau-217) (positive or intermediate via validated assays) ≤ 365 days prior to screening or between screening and randomisation or a positive amyloid PET scan (if available) or a positive amyloid CSF test (if available) 5. Randomisation should ideally take place within 4 weeks of the screening visit but no later than 8 weeks after the screening visit 6. Must be able and willing to comply with the treatment and assessment schedule and requirements including being able to start trial treatment ≤ 2 weeks after randomisation 7. Willing and able to have MRI scans in accordance with the assessment schedule unless participant is clinically contraindicated due to:\n\n  \u003C!-- -->\n\n  1. Pacemakers or defibrillators (unless MRI-conditional models)\n  2. Aneurysm clips, stents or metal implants (unless MRI safe)\n  3. Cochlear implants (unless MRI-conditional models)\n  4. Metal fragments in the body\n  5. Severe claustrophobia 8. Negative pregnancy test ≤4 weeks prior to randomisation for women of child-bearing potential 9. Normal liver function at screening consisting of all the following:\n\n  \u003C!-- -->\n\n  1. Total serum bilirubin \\\u003C1.5 x ULN (except for participants with Gilbert's disease, for whom the upper limit of total serum bilirubin is 51.3 μmol\u002Fl or 3mg\u002Fdl)\n  2. Alanine aminotransferase (ALT) \\\u003C3 x ULN;\n  3. Alkaline phosphatase \\\u003C3 x ULN 10. Documented participant and study partner informed consent 11. If a participant is being re-randomised into the trial, additional timing of entry requirements must also be met:\n\n  \u003C!-- -->\n\n  1. For participants being re-randomised after completing 18 months' follow-up and the arm was not closed due to lack of activity, a 12-week washout period from last dose of IMP must be completed before their screening visit. If the efficacy analysis indicates that the IMP was ineffective then this washout period can be reduced to 6 weeks.\n  2. For participants being re-randomised following treatment arm termination due to lack of activity, a 6-week washout period from their last dose of IMP must be completed prior to screening assessment\n\n     Study Partner inclusion criteria:\n     1. Participant that meets the AD-SMART eligibility criteria has consented to participation in the trial\n     2. Has at least twice-weekly contact with participant\n     3. Be 18 years or older at the time of providing consent\n     4. Willing to complete study partner questionnaires as outlined in visit schedule\n     5. Willing to attend remote and in-person study visits with participant\n     6. Documented informed consent\n\n     Exclusion Criteria:\n* Patient meets none of the exclusion criteria:\n\n  1. Fazekas Score =3 reported from an MRI taken at any time prior to randomisation, if an MRI is not clinically contraindicated (reasons specified in Inclusion Criteria 7) A. MRI does not need to be repeated if Fazekas score = 0, 1 or 2 reported from an MRI performed ≤365 days to screening visit (if Fazekas score has not been reported, refer to Section 7.4) b. MRI should be conducted if participant is not clinically contraindicated to MRIs and previous MRI where Fazekas score = 0, 1 or 2 was \\>365 days or previous MRI scan is not available for Fazekas score reporting or participant has never had an MRI\n  2. Clinical diagnosis of Dementia with Lewy bodies\n  3. Clinical diagnosis of Parkinson's disease\n  4. Clinical diagnosis of Frontotemporal Dementia\n  5. Cardiac failure (American Heart Association Stage C or D)\n  6. Significant respiratory comorbidity (hospitalisation within the previous ≤6 months due to respiratory comorbidity)\n  7. Renal failure (CKD IV or eGFR ≤45 mL\u002Fmin\u002F1.73m²) at any time point prior to randomisation\n  8. Malignancy (except if in complete remission) e.g. solid organ or haematological or melanoma\n  9. Score of ≥1 on C-SSRS at screening visit\n  10. Individuals without an identified study partner (refer to Section 4 for further details on study partners)\n  11. Individuals who have an Alzheimer's Disease or Central Nervous System medication (e.g. antidepressant) change or dose change ≤28 days prior to screening\n  12. Use of an Investigational Medicinal Product (IMP) or Investigational Medical Device (IMD) ≤26 weeks prior to randomisation (except for AD-SMART participants that are being re-randomised. See Section 5.4 for further information).\n  13. Receiving antibody-based amyloid clearing treatment for Alzheimer's Disease within 26 weeks prior to randomisation\n  14. Unable or unwilling to comply with study procedures\n  15. Unable to swallow whole capsules\n  16. Individuals who are living in the same household as an AD-SMART participant who is actively taking trial medication\n  17. Female participants that are pregnant or breastfeeding\n  18. Women of child-bearing potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception (see acceptable methods of contraception) whilst on trial treatment and up to 12 weeks after the last dose of study drug\n  19. Male participants with a partner of child-bearing potential unwilling or unable to use an acceptable method of contraception whilst on trial treatment and up to 12 weeks after the last dose of the study drug.\n  20. Male participants unwilling to desist from sperm donation during the trial and for 12 weeks after the last dose of trial treatment\n  21. Current or previous exposure to any of the currently recruiting AD-SMART IMPs ≤26 weeks before randomisation.\n  22. History of alcohol and\u002For drug abuse and\u002For dependence within the 5 years prior to screening visit.\n  23. Any concurrent medical condition, abnormal laboratory tests or uncontrolled, clinically significant systemic disease that, in the opinion of the Investigator, could cause study participation to be detrimental to the participant.\n  24. Participants who are not eligible for any of the trial IMPs, according to the eligibility criteria listed in the individual drug appendices. Please note that participants can enter the trial if they are eligible for at least one of the trial treatment arms, but do not need to be eligible for all.\n\nArm-specific eligibility criteria:\n\nAtomoxetine-specific exclusion eligibility criteria:\n\nIn addition to the core inclusion and exclusion criteria, refer to section 2.2 of AD-SMART Appendix 1 Atomoxetine' for the arm-specific exclusion eligibility criteria for the Atomoxetine arm which must also be met.\n\nMetformin-specific exclusion eligibility criteria:\n\nIn addition to the core inclusion and exclusion criteria, refer to section 2.2 of AD-SMART Appendix 2 Metformin' for the arm-specific exclusion eligibility criteria for the metformin arm which must also be met.","55 Years",{"count":83,"type":21},1200,[59],"A multicentre, interventional, multi-arm, multi-stage Phase 3 trial including randomisation, double blinding, placebo control evaluation of treatments for sustained clinical response (18 months) in symptomatic Alzheimer's Disease in a population representative of people with Alzheimer's disease in the UK.",[26,87,88],"Mild Cognitive Impairment Due to Alzheimer's Disease","Alzheimer Disease Dementia","2026-07-21",{"date":91,"type":38},"2026-07-23",{"date":93,"type":21},"2026-07-24",{"date":95,"type":21},"2031-03",{"name":97,"class":45},"University College, London",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100589342","cognitive-health-in-ageing-register-investigational-and-observational-trial-studies-in-dementia-research-chariot-prospective-readiness-cohort-pro-longitudinal-study-100589342","NCT06953167","Cognitive Health in Ageing Register: Investigational and Observational Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort (PRO) Longitudinal Study","CPLS","Inclusion Criteria:\n\n* To be eligible, participants must meet all inclusion criteria for the study, as follows:\n\n  1. Male or Female, aged \\>65years\n  2. Willing and having capacity (as assessed according to MCA 2005) to provide written informed consent and to participate in the study, OR (if lacking capacity) has a nominated consultee (as described in the MCA 2005 and Chapter 11 of the MCA Code of Practice 2007) who is able to advise that this is what the participant would have wished.\n  3. Have completed CPSS1 amyloid screening using either amyloid PET scanning or CSF Aβ42 measurement.\n  4. Be fluent in and able to read and write in English and have adequate hearing and visual acuity to complete the required psychometric tests.\n  5. Be willing and able to adhere to the study visits and assessments specified in this protocol, and the reasonable requests and expectations of the study staff.\n  6. Have a reliable informant - study partner (relative, partner, or friend) who is willing to provide their informed consent to participate, as a source of information. The study partner must be over 18 years old and should be fluent in and able to read and write in English. The informant must have sufficient contact with the participant and sufficient cognitive ability such that the Investigator feels that they can provide meaningful information about the participant's daily functioning. At a minimum, they must be in contact with the participant at least twice per month (in person, via telephone or other audio\u002Fvisual communication). The study partner will be required in-person at the V1 visit. However, they can complete all subsequent visits remotely, or in-person if required.\n\nExclusion Criteria:\n\n* To be eligible, participants must not meet any of the exclusion criteria for the study, as follows:\n\n  1. Participant has any disability that would prevent completion of study procedures or assessments (e.g. blindness or significant visual impairment, deafness or significant hearing impairment, speech impairment, or sensory or motor dysfunction), or has any condition or situation\u002Fcircumstance for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g. compromise the participant's well-being), or that could prevent, limit, or confound the results of protocol-specified assessments and cognitive testing.\n  2. Unable to comply with the study-specific requirements.\n  3. History of alcohol or drug dependence or abuse, as defined by the most current version of the DSM criteria within the last 3 years.","65 Years",{"count":108,"type":21},600,"Alzheimer's disease is a degenerative condition affecting the brain and is the most frequent form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people. The progression of the disease varies between individuals and the early stages may be characterised by only minimal changes in memory and thinking. These changes could remain undetected as the symptoms may be mistakenly regarded as normal age-related forgetfulness. However, dementia is not part of the normal ageing process.\n\nThe disease process is now known to start at least 20 years prior to the emergence of symptoms. A protein called amyloid starts to deposit in the brain, forming clumps referred to as 'plaques'. Another protein called tau sticks to other tau molecules inside the brain cell and forms structures called 'tangles'. These changes cause damage to the brain cells, disrupting their normal functioning, leading to inflammation and ultimately destruction of the brain cells.\n\nSo far, there is no cure for Alzheimer's disease, but by better understanding the changes that occur over time in the brain, scientists can find ways of detecting and therefore diagnosing and treating the disease earlier. One way in which scientists learn about how a disease develops, is by following people unaffected by the condition over an extended period of time. The same tests and sample collections are repeated to monitor any clinical changes. These are known as longitudinal studies, and CHARIOT:PRO studies are examples of this.\n\nThe CHARIOT:PRO Longitudinal Study (CPLS) is an observational study of 600 participants aged \\>65 years old which aims to evaluate cognition (thinking abilities) and biomarkers (biological markers which indicate the presence of disease e.g. amyloid) over time in older adults. The participants in CPLS were all screened as part of the CHARIOT:PRO Sub-Study (CPSS1) in 2015-2017.\n\nVisit 1 will be conducted within eight weeks after the Study Entry Visit (SEV). Visits 2-7 will follow at six-monthly intervals from Visit 1. During visits, information relating to health, medication, family history of dementia, self-reported cognitive function and anthropometrics will be collected. The cognitive assessments PACC5 and RBANS will be administered along with a measure of executive function (Trail Making Test). Participants will be provided with self-reported questionnaires to be completed at each onsite visit. Blood samples will be taken once a year i.e. Month 0, 12, 24 and 36.\n\nThe purpose of CPLS is to continue to build on the vital data and samples already kindly donated by participants screened for CPSS1. This will provide valuable information that will enhance understanding of the earliest stages of Alzheimer's disease before obvious symptoms start to appear. Importantly, the Investigators hope to identify predictive markers of disease, which will help doctors to select the right drugs, and develop other approaches like lifestyle guidance to prevent or delay Alzheimer's disease in the future.\n\nThis study is sponsored by Imperial College London, led by the Principal Investigator Professor Lefkos Middleton and is funded by Gates Ventures.",[26],[112,32,113,114,115,116,117,118],"Alzheimer's disease","Longitudinal Study","Biomarkers","CHARIOT-PRO","Amyloid","Cognition","Mild Cognitive Impairment","2026-01-19",{"date":121,"type":38},"2026-01-21",{"date":123,"type":38},"2025-03-17",{"date":125,"type":21},"2029-02",{"name":127,"class":45},"Imperial College London",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":57,"phases":139,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":46},"100590257","cervical-lymphatico-venous-bypass-for-treatment-of-alzheimers-disease---proof-of-concept-study-clyveb-ad-1-study-100590257","NCT06965062","Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept Study (CLyVeB-AD-1 Study)","CLyVeB-AD-1","Inclusion Criteria:\n\n* Diagnosis of mild-moderate Alzheimer's disease (based on NIA-AA criteria);\n* Mini-Mental State Examination (MMSE) score 10-22;\n* Both participants and caregiver are able to understand English or Mandarin\n* Ability to provide informed consent or have a legally authorised representative to provide informed consent;\n* Good family support for post-treatment care and rehabilitation;\n* Fit for general anaesthesia\u002Fdeep sedation and surgery (ASA 1-2; excluding the diagnosis of Alzheimer's Disease).\n\nExclusion Criteria:\n\n* Cognitive decline due to prior infection or autoimmune diseases;\n* History of major cerebrovascular events or significant cardiovascular diseases;\n* Inability to have the head turned passively by at least 40 degrees;\n* Previous neck lymph node surgery or irradiation;\n* Active infection or malignancy;\n* Any contraindications to surgery or lumbar puncture\n* Any contraindication to MRI\u002FPET scan (eg. metallic implant that are not MRI-safe, known radiotracer allergy)\n* Experimental Alzheimer's Disease treatment within the past 6 months. • Current use of monoclonal antibodies treatment (eg. lecanemab\u002Fdonanemab)","50 Years","80 Years",{"count":138,"type":21},10,[140],"NA","Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie. amyloid, tau) are purported to lead to neuroinflammation, synaptic dysfunction and cognitive decline. The available pharmacotherapy provide limited symptomatic control, modest effect on disease progression with significant risk of side effects. Patients with AD eventually run out of effective pharmacotherapy and deteriorate.\n\nRecent evidence implicated the glymphatic system, meningeal lymphatics of the brain, and downstream drainage to the cervical lymphatic system in the accumulation of neurotoxic proteins in AD. This presented the opportunity for extra-cranial intervention, and has since been demonstrated in preclinical models. Based on these development, Xie and colleagues pioneered the deep cervical lymph node to venous bypass (DCLNV-BP) procedure with very promising early outcomes. The observed improvement had been attributed to enhanced clearance of the neurotoxic proteins. Knowledge gap and clinical equipoise remain, and clinical trials are required to understand the safety, mechanism of action, patient selection, and long-term outcomes.\n\nIn this proof of concept study, the investigators aim to assess safety and preliminary efficacy of DCLNV-BP in AD. An approach using objective clinical assessments, biomarkers and neuroimaging, to assess safety, evaluate preliminary efficacy and elucidate the possible mechanism underlying the observed effects, is undertaken. Since there are limited effective treatment for AD, this procedure is potentially ground breaking if it proves to halt progression or even improve patients' cognition, function and behaviour. Indirectly, this will have enormous health economic benefit for Singapore and the developed world that is facing the silver tsunami. Findings from this pilot study will lay the groundwork for future trials and research collaboration in AD and other neurodegenerative diseases.",[143,144,145,146,26],"Alzheimer Disease","Dementia Alzheimer Type","Dementia Alzheimer's Type","Alzheimer's Disease",[148,32,149,150,151,152,153,154],"Alzheimer's Disease","lymphatic surgery","lymphaticovenous anastomosis","lymphaticovenous bypass","cervical lymph node","meningeal lymphatic system","glymphatic system","2026-01-11",{"date":157,"type":38},"2026-01-13",{"date":159,"type":38},"2025-04-01",{"date":161,"type":21},"2030-03-31",{"name":163,"class":45},"Vincent Tay Khwee Soon",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":16,"sex":17,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":57,"phases":176,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":46},"100592608","improving-executive-control-in-cognitively-healthy-older-adults-the-multitasking-strategy-must-study-100592608","NCT06995638","Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study","Web-based Technology and Cognitive Training: Improving Executive Control in Cognitively Healthy Older Adults: the MUltitasking STrategy (MUST) Study","MUST","Inclusion Criteria:\n\n* Age 60-75\n* Adequate English proficiency\n* Willingness to adhere to training protocol:\n\n  * Attend 2 in-person assessments\n  * Attend a blood test\n  * Attend online intervention sessions and online follow-up assessment\n\nExclusion Criteria:\n\n* Low test scores (below 26 on the Montreal Cognitive Assessment)\n* Known history of cognitive impairment, dementia, stroke, seizure disorder, or other neuropsychiatric condition judged to impact cognitive performance.\n* Taking medications known to influence cognitive performance.\n* Sensory (e.g. visual, auditory) or physical (e.g. severe arthritic, orthopedic, neurologic) impairment incompatible with use of a standard computer workstation.\n* Enrolled in a concurrent study that could affect the outcome of this study.","60 Years","75 Years",{"count":175,"type":21},130,[140],"Developing efficient cognitive intervention for cognitively health older adults is a major public health goal, due to its potential for reducing age-related cognitive decline and Alzheimer's disease\u002Fdementia risk. Executive Control is a relevant cognitive target since it declines with aging and is critical for multi-tasking in daily life. The proposed research investigates whether playing a web-based cognitive complex game (the Breakfast Game) impacts cognitive performance in cognitively healthy older adults. To be enrolled in the study, participants will be asked to undergo a cognitive sassessment, health questionnires, and a blood exam. The intervention consist in one educational session on healthy aging, and 10 one-hour cognitive training sessions 2-3 times a week over one month. Participants will be asked to repeat the cognitive assessment within 1-2 weeks after the intervention, and after three months.",[179,26],"Healthy Aging",[181,117,182,183,184,185],"Aging","Executive Functions","Randomized Controlled Trial","Cognitive Training","Neuropsychology","2025-12-09",{"date":188,"type":38},"2025-12-15",{"date":190,"type":38},"2025-12-10",{"date":192,"type":21},"2027-12",{"name":194,"class":45},"Rutgers, The State University of New Jersey",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":173,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":46},"100601089","radiolabeled-tspo-targeted-molecular-probe-in-alzheimers-disease-100601089","NCT07105956","Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease.","Clinical Application of a Novel Radiolabeled Translocator Protein (TSPO) Targeted Small Molecular Probe in Neuroinflammation Imaging of Alzheimer's Disease.","Inclusion Criteria:\n\n* Volunteer for the trial, with the patient or their legal guardian signing the informed consent form.\n* Volunteers are not limited by gender, and the age range is from 18 to 75 years old, including both ends.\n* The patient is diagnosed with Alzheimer's disease (AD), supported by a positive amyloid PET scan.\n* The patient has completed Tau PET scan.\n\nExclusion Criteria:\n\n* Individuals with a history of allergy to drugs chemically or biologically similar to TSPO, a history of atopy, or currently suffering from allergic diseases.\n* Use of anti-inflammatory drugs, including corticosteroids and immunosuppressants, within the past 14 days, which may interfere with the accuracy of inflammation imaging.\n* Presence of other coexisting neurological diseases, such as stroke, Parkinson's disease, brain tumors, or mental disorders, including depressive disorder and schizophrenia.\n* Severe cardiac, pulmonary, hepatic, or renal dysfunction, or uncontrolled systemic diseases; 5. Presence of metal implants contraindicated for MRI, including but not limited to cardiac pacemakers, artificial heart valves, and metal stents.\n* Claustrophobia or inability to tolerate prolonged examinations.\n* Pregnant women (defined as those with a positive urine pregnancy test) or breastfeeding women.\n* Patients whose physical condition is unsuitable for radioactive tracer-based imaging examinations.\n* Other circumstances deemed unsuitable for participation in the trial by the researcher.",{"count":203,"type":21},8,"Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \\[68Ga\\]-DOTA-HK-011 in neuroinflammation imaging of Alzheimer's disease.",[26],"NOT_YET_RECRUITING","2025-07-30",{"date":209,"type":38},"2025-08-06",{"date":211,"type":21},"2025-09-01",{"date":213,"type":21},"2026-08-31",{"name":215,"class":45},"Nanjing First Hospital, Nanjing Medical University",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":16,"sex":17,"minAge":172,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":57,"phases":226,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":4},"100587925","phase-1-vr-based-physical-activity-and-reminiscence-therapy-100587925","NCT06934720","VR-based Physical Activity and Reminiscence Therapy","Active Physical Activity - Virtual Reality Cognitive Therapy","Inclusion Criteria:\n\n* older adults in the setting who have the ability to pedal the rehabilitation bike\n\nExclusion Criteria:\n\n* Individuals self-reporting or identified by stakeholders as unwilling or unsuitable to participate.","100 Years",{"count":225,"type":21},100,[227,228],"PHASE1","PHASE2","The goal of this clinical trial is to learn if active Physical activity + virtual reality cognitive therapy (aPAVRCT) works to slow the progression of AD cognitive decline in older adults. It will also learn about the physical effects and mental effects of the aPAVRCT. The main questions it aims to answer are:\n\nDoes aPAVRCT slow the progression of AD cognitive decline? (e.g., HK-MoCA, ADAS-Cog) Does aPAVRCT improve physical function? (e.g., ADL) Does aPAVRCT improve mental health? (e.g., GDS-15, PANAS) Does aPAVRCT improve life satisfaction? Does aPAVRCT improve other cognitive or physical capacities? What issues and benefits do participants and stakeholders (e.g., families, caregivers, managers) have when taking aPAVRCT? (e.g., NPI-Q) Researchers will compare the intervention group (aPAVRCT) to a control group (rehabilitation bike) to see if aPAVRCT works to slow the progression of AD in cognitive decline.\n\nParticipants will:\n\nTake aPAVRCT (interventional group) or usual physical acitvity (control group) at least twice a week, 15 minutes for each session, for 12-16 weeks Physiotherapies (assistants) and care professionals will do the intervention, research group will operate, observe, and assist the experiment.\n\nAll the experiment processes will be recorded. Visit the sites everyday for checkups and tests Keep a diary of their symptoms, the number of times, and any essential information\n\nSites: around 3-5 nursing homes, under one institution. Inclusion criteria: older adults in the setting who have the ability to pedal a rehabilitation bike.",[32,231,62,232,233,26,234],"Neurodegenerative Disease","Virtual Reality","Physical Activity","Cognitive Therapy","2025-05-18",{"date":237,"type":38},"2025-05-22",{"date":239,"type":21},"2025-05-19",{"date":241,"type":21},"2027-04-15",{"name":243,"class":45},"Hong Kong University of Science and Technology",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":253,"conditions":254,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":46},"100587128","multimodal-ophthalmic-imaging-and-plasma-biomarkers-for-the-early-detection-of-alzheimers-disease-100587128","NCT06924359","Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease","MOIPAD","Inclusion Criteria:\n\n* Male or female participants aged ≥ 50 years;\n* Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN);\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Presence of other neurological disorders and systemic diseases that may cause cognitive impairment;\n* Inability to cooperate with cognitive assessments;\n* Refusal to undergo blood sampling.",{"count":252,"type":21},200,"With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).",[26],"2025-04-06",{"date":257,"type":38},"2025-04-11",{"date":259,"type":38},"2025-03-19",{"date":261,"type":21},"2027-08-31",{"name":263,"class":45},"Peking University First Hospital"]